Simon Powell

@rweichselbaum haha - not quite there, but I am trending!

@simonpowell213 Only 10?😢🥸

When I was a teenager, the average life expectancy for men was 68. Now that I have exceeded that age, the world looks very different. I succeeded with most of my first 10 grant applications; now I have to write 10 applications to have a chance that one will be funded. Aging!

1/N Finally out!! -- 30Gy for HPV+OPC in @JCO_ASCO – work by the @MSKCancerCenter Head and Neck team, led by @imrtlee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JC…

@CJTsaiMDPhD @TallAllen @TheLancet @MSK_RadOnc @MSKCancerCenter @MSKBiostats @RadMedPM @UofTDRO @thePMCF @pmcancercentre @JYangMDPhD @ipreeshagul They are different populations, but if SBRT works for more extensive disease, it usually extrapolates to earlier stage disease, even if it takes longer to see the effect. There are disease patterns of limited mets that we need to understand...

@TallAllen @TheLancet @simonpowell213 @MSK_RadOnc @MSKCancerCenter @MSKBiostats @RadMedPM @UofTDRO @thePMCF @pmcancercentre @JYangMDPhD @ipreeshagul They are completely different patient populations. (Oligomet vs oligoprogression)

1)🚨Just out @TheLancet - CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer. thelancet.com/journals/lance… @simonpowell213 @MSK_RadOnc @MSKCancerCenter @MSKBiostats @RadMedPM @UofTDRO @thePMCF @pmcancercentre @JYangMDPhD @ipreeshagul @PamelaDrullins1 @ErinGillespieMD @imrtlee @xrtGenomics @charlesrudin @DanHigginsonMD @AmyXuMDPhD @theRADSofKHAN @DKirschMDPhD @ldawsonmd

@CJTsaiMDPhD @TheLancet @MSK_RadOnc @MSKCancerCenter @MSKBiostats @RadMedPM @UofTDRO @thePMCF @pmcancercentre @JYangMDPhD @ipreeshagul When this trial was planned, there was still a lot of resistance to considering SBRT for oligoprogression. There is clearly a role for this approach in NSCLC, but rationalizing with the LU002 still needs work. CtDNA might be a discriminator for success!

@jeremy_setton @MSKCancerCenter Lots of exciting projects in homologous recombination (HR) and HR-deficiency. Great lab, great location!

The Powell lab is hiring! Two funded post-doctoral positions. Come join us in NY @MSKCancerCenter! @simonpowell213 shorturl.at/bzFPY

@Lohman_Lab @bradwouters could be better!

@bradwouters @simonpowell213 Congrats Simon. How's that handicap?

Congratulations @simonpowell213 - well deserved!

@DrPhilKantoff @MSKCancerCenter Thanks Phil, a one of kind week - when everyone wanted to shake my hand or take a selfie with me...

@MSKCancerCenter @simonpowell213 Congratulations Simon!

That smile says it all! Congratulations, @simonpowell213!

@krupali @MSKCancerCenter Tom Brady's 6 for the Pats - copies!! I was at 3 of the games - such great memories

@MSKCancerCenter @simonpowell213 Are those all superbowl rings?

@aadel_chaudhuri @MSKCancerCenter Thanks Aadel. We need people like you to take over...

@MSKCancerCenter @simonpowell213 Huge congrats @simonpowell213 on the ASTRO gold medal!!! Inspirational physician-scientist.

@bradwouters Thanks Brad - what a week!

@RichBarakatMD @DrPhilKantoff @MSKCancerCenter Thanks Rich! So much attention! I am not shy, but this week is quite something!

@DrPhilKantoff @MSKCancerCenter @simonpowell213 Congrats Simon!

@jmmrad @JulieSchwarz14 @WashURadOnc @ASTRO_org Carlos was a true gentleman and a giant in our field. It was a great honor to become the 2nd Chair of the Department in 2004. He attended ASTRO every year after retiring and last year confessed that he hardly knew anyone anymore! Dedicated to the end.

It is with profound sadness that I share the news of today's passing of Dr. Carlos A Perez, former Chair of Radiation Oncology at Washington University and the Mallinckrodt Institute of Radiology. @WashURadOnc @ASTRO_org beckerexhibits.wustl.edu/mig/bios/perez…

@rweichselbaum @MSKCancerCenter @Nature @jeremy_setton @skimomiks Thanks Ralph!

@MSKCancerCenter @Nature @jeremy_setton @simonpowell213 @skimomiks Congratulations Simon!( et Al😊)

A new @Nature study from @jeremy_setton, @simonpowell213, @skimomiks & team reveals new classes of genome rearrangements specific to BRCA1 / BRCA2 deficiency. The approach could greatly expand the pool of patients who would benefit from HRD therapies. nature.com/articles/s4158…

I have been in the US over 30 yrs and for most of that time we have worried about healthcare reform. In reality, almost nothing has changed. The cost of healthcare is going to continue to rise, so we need a fundamental change in approach or, like social security, it will break.

@gillies_mckenna Memorial treated patients at ProCure in New Jersey from 2013 to 2019. The patients are filtered by who were capable of traveling to that site. Selection also by who would have improved dose distribution with protons versus IMRT.

@HenningWillers @MGHCancerCenter @ASTRO_org @RRS_RadRes @ASTRO_Chair @_MichaelBaumann @SorenBentzen @profOvergaard @gillies_mckenna @DKirschMDPhD @rweichselbaum @bradwouters @CatharineWest3 Herman changed my life by bringing me to the USA over 30 years ago and the only question he ever wanted to ask was about the latest research. One of a kind.

1/ It is with great sorrow💔to let you know that Herman D Suit MD DPhil ◾️Former Chair of #radonc @MGHCancerCenter ◾️A Giant in the field #radonc #radbio #medphys ◾️'Father' of #protontherapy ◾️Former president of @ASTRO_org @RRS_RadRes has passed away at the age of 93😢

@DrBenNeel Ben - you are more conscientious than most! I follow your philosophy - just show me what I need to make the paper convincing. Don't rewrite the paper!

2/13 and 2yrs on. The time spent working on a paper today? 4-8 years! Average time spent by a reviewer on the paper? 40-80 minutes! Let's write papers more clearly but, as reviewers, let's give them the respect they deserve!